IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v9y2018i1d10.1038_s41467-018-03905-6.html
   My bibliography  Save this article

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Author

Listed:
  • Ovidiu C. Andronesi

    (Harvard Medical School)

  • Isabel C. Arrillaga-Romany

    (Harvard Medical School)

  • K. Ina Ly

    (Harvard Medical School)

  • Wolfgang Bogner

    (Medical University of Vienna)

  • Eva M. Ratai

    (Harvard Medical School)

  • Kara Reitz

    (Harvard Medical School)

  • A. John Iafrate

    (Harvard Medical School)

  • Jorg Dietrich

    (Harvard Medical School)

  • Elizabeth R. Gerstner

    (Harvard Medical School)

  • Andrew S. Chi

    (New York University Langone Medical Center and School of Medicine)

  • Bruce R. Rosen

    (Harvard Medical School)

  • Patrick Y. Wen

    (Dana-Farber Cancer Institute)

  • Daniel P. Cahill

    (Harvard Medical School)

  • Tracy T. Batchelor

    (Harvard Medical School)

Abstract

Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evidence of the pharmacodynamics of a new mutant IDH1 inhibitor in glioma patients, using non-invasive 3D MR spectroscopic imaging of 2HG. Our results from a Phase 1 clinical trial indicate a rapid decrease of 2HG levels by 70% (CI 13%, P = 0.019) after 1 week of treatment. Importantly, inhibition of mutant IDH1 may lead to the reprogramming of tumor metabolism, suggested by simultaneous changes in glutathione, glutamine, glutamate, and lactate. An inverse correlation between metabolic changes and diffusion MRI indicates an effect on the tumor-cell density. We demonstrate a feasible radiopharmacodynamics approach to support the rapid clinical translation of rationally designed drugs targeting IDH1/2 mutations for personalized and precision medicine of glioma patients.

Suggested Citation

  • Ovidiu C. Andronesi & Isabel C. Arrillaga-Romany & K. Ina Ly & Wolfgang Bogner & Eva M. Ratai & Kara Reitz & A. John Iafrate & Jorg Dietrich & Elizabeth R. Gerstner & Andrew S. Chi & Bruce R. Rosen & , 2018. "Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate," Nature Communications, Nature, vol. 9(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03905-6
    DOI: 10.1038/s41467-018-03905-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-018-03905-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-018-03905-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03905-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.